Prosecution Insights
Prosecution Insights
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| §112 only | 1 (20%) |
| No statute on record | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIBSHMAN, SARAH GRACE | 1 | 40.9% | +46.3% |
| JACKSON, SHAWQUIA | 1 | 77.9% | -3.4% |
| ROMERO, KRISTEN WANG | 1 | 71.4% | +29.6% |
| MOORE, SUSANNA | 1 | 68.1% | +31.8% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17045916 | METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS | VALENROD, YEVGENY | 45d overdue |
| 19198975 | COMBINATION THERAPY USING A CD47-SIRP alpha BLOCKING AGENT AND AZACITIDINE | HIBSHMAN, SARAH GRACE | 16d overdue |
| 18564384 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | ROMERO, KRISTEN WANG | 8d overdue |
| 18044329 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | MOORE, SUSANNA | 6d |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1693 | 1 |
| 1626 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19198975 | COMBINATION THERAPY USING A CD47-SIRP alpha BLOCKING AGENT AND AZACITIDINE | HIBSHMAN, SARAH GRACE | 1693 | §103 | Final Rejection | 16d overdue | Pending | May 05, 2025 |
| 18406841 | Method for Treating Diseases Using SMARCA2/4 Degraders | JACKSON, SHAWQUIA | 1626 | §112 | Non-Final OA | 30d overdue | Pending | Jan 08, 2024 |
| 18564384 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | ROMERO, KRISTEN WANG | 1624 | Other | Non-Final OA | 8d overdue | Pending | Nov 27, 2023 |
| 18044329 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | MOORE, SUSANNA | 1624 | §103 | Final Rejection | 6d | Pending | Mar 07, 2023 |
| 17045916 | METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS | VALENROD, YEVGENY | 1628 | Other | Final Rejection | 45d overdue | Pending | Oct 07, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial